Standard BioTools and Treeline Biosciences announce merger agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Standard BioTools and Treeline Biosciences Announce Merger Agreement
June 8, 2026 7:30 AM EDTCombined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates
Company to be led by Treeline CEO and co-founder Josh Bilenker, MD, and experienced team of proven drug developers
Treelines pipeline includes three Phase 1 programs with multiple anticipated clinical data readouts beginning in 2027
Well capitalized with over $900 million in cash expected at closing, providing runway into 2029
Supplemental investor materials, including management remarks, posted on Standard BioTools website
BOSTON, Mass. and... More
